Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

28.54 +0.15 (+0.53%)
Streaming Delayed Price Updated: 11:56 AM EDT, Sep 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,941,566
Open 28.43
Bid (Size) 28.54 (13)
Ask (Size) 28.55 (28)
Prev. Close 28.39
Today's Range 28.40 - 28.80
52wk Range 25.20 - 36.29
Shares Outstanding 5,606,688,356
Dividend Yield 5.75%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Walgreens Boots Alliance Fell Another 22% in August
The retail pharmacy giant faces ever-mounting headwinds. 
Via The Motley Fool
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included a higher-than-expected U.S. price for Yorvipath and a delayed cash flow... 
Via Benzinga

Performance

YTD
-4.00%
-4.00%
1 Month
-4.03%
-4.03%
3 Month
-3.42%
-3.42%
6 Month
+4.97%
+4.97%
1 Year
-19.33%
-19.33%

More News

Read More
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
Via FinancialNewsMedia
Exposures COVID-19
A Closer Look at Pfizer's Options Market Dynamics
Via Benzinga
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
From FN Media Group LLC
Via GlobeNewswire
3 Bargain-Priced Growth Stocks for Fall 2024
Via MarketBeat
Topics Economy
Exposures COVID-19 Economy
Therma Bright Congratulates John Patton, PhD of InStatin on Receiving the Prestigious Charles G. Thiel Award
Via Newsfile
UK, Taiwan Approve Moderna's Updated COVID-19 Shot
Via Benzinga
Exposures COVID-19
Pfizer And Valneva Partnered Lyme Disease Vaccine Shows Effectiveness As Booster Shot In Mid-Stage Study
Via Benzinga
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher
Via Benzinga
Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market
Via Investor's Business Daily
Why Is BridgeBio Pharma Stock Trading Higher On Friday?
Via Benzinga
Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles
Via Benzinga
Alnylam Plummets, Reversing 50% Gain This Year, As Pfizer Rival Lags Expectations
Via Investor's Business Daily
2 Incredibly Cheap Growth Stocks to Buy Now
Via The Motley Fool
2 Incredibly Cheap Healthcare Stocks to Buy Now
Via The Motley Fool
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
Via Investor's Business Daily
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
2 Beaten-Down S&P 500 Dividend Stocks to Buy on the Dip and Hold Forever
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 Ways the Democratic Party's Platform Could Impact Biotech and Pharma Stocks if Implemented
Via The Motley Fool
Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare
From Pfizer Inc.
Via Business Wire
Americans To Access COVID-19 Test Kits For Free As US Government Restarts Free At-Home Program
Via Benzinga
Exposures COVID-19
Eli Lilly’s Path to the Next Trillion Market Capitalization
Via MarketBeat
Is Pfizer Stock Still a Buy After an Unexpected Setback?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.